Figure 8
Figure 8. SNP-A karyotyping allows both mapping of invariant lesions and improvement of detection rate of cytogenetic abnormalities. (A) Mapping of chromosomal aberrations in myeloid malignancies. Karyograms generated by SNP-A allow for mapping of the location of chromosomal aberrations and delineation of minimal commonly deleted regions (as an example, topography of lesions on chromosome 7 is shown based on the analysis of a cohort of patients with AML and MDS). (B) Summary of the SNP-A karyotyping results. In representative studies of patients, including 78% of MDS, 75% of MPD/MDS, 87% of sAML,32 30% of AA (M. Wlodarski, L. Gondek, C. L. O'Keefe, R. Tiu, A. Haddad, A. Risitano, J.P.M., manuscript submitted May 2008), and 56% of primary AML (R. Tiu, C. L. O'Keefe, M. Sekeres, M. A. McDevitt, J. Karp, J.P.M., manuscript submitted June 2008) patients were analyzed using SNP-A, and the rates of detection of chromosomal abnormalities, including UPD, were calculated.

SNP-A karyotyping allows both mapping of invariant lesions and improvement of detection rate of cytogenetic abnormalities. (A) Mapping of chromosomal aberrations in myeloid malignancies. Karyograms generated by SNP-A allow for mapping of the location of chromosomal aberrations and delineation of minimal commonly deleted regions (as an example, topography of lesions on chromosome 7 is shown based on the analysis of a cohort of patients with AML and MDS). (B) Summary of the SNP-A karyotyping results. In representative studies of patients, including 78% of MDS, 75% of MPD/MDS, 87% of sAML,32  30% of AA (M. Wlodarski, L. Gondek, C. L. O'Keefe, R. Tiu, A. Haddad, A. Risitano, J.P.M., manuscript submitted May 2008), and 56% of primary AML (R. Tiu, C. L. O'Keefe, M. Sekeres, M. A. McDevitt, J. Karp, J.P.M., manuscript submitted June 2008) patients were analyzed using SNP-A, and the rates of detection of chromosomal abnormalities, including UPD, were calculated.

Close Modal

or Create an Account

Close Modal
Close Modal